Bringing doctors together

or

A free, private network for verified physicians

  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease

    Nov 7, 2026DOI: 10.1056/nejmoa2612126Original ArticleNEJM

    Written by: Paul M Ridker, M.D.A. Michael Lincoff, M.D.Nikolaus Marx, M.D.Ann Marie Navar, M.D.Naveed Sattar, M.B., Ch.B.Katherine R. Tuttle, M.D.Matthew Budoff, M.D.Morten Böttcher, M.D.Matthew A. Cavender, M.D.Robin P. Choudhury, D.M.Jan H. Cornel, M.D.Grzegorz Gajos, M.D.Issei Komuro, M.D.K.M.K. Reddy Parvathareddy, M.D.Roberto Pontremoli, M.D.José Francisco Kerr Saraiva, M.D.Iana I. Simova, M.D.Lance A. Sloan, M.D.Alejandro López-Suárez, M.D.Yi-Da Tang, M.D.Lale Tokgözoğlu, M.D.Nqoba Tsabedze, M.D.Konstantinos Tsioufis, M.D.Subodh Verma, M.D.Mathias Vrolix, M.D.Andreas Andersen, Ph.D.Florian M.M. Baeres, M.D.Kathrine Ekström, M.D.Mads D.M. Engelmann, M.D.Sofia Gerward, M.D.G. Kees Hovingh, M.D.Anders Hvelplund, M.D.Vlado Perkovic, M.B., B.S.

    Summary

    In patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation, ziltivekimab decreased interleukin-6 levels but did not result in fewer cardiovascular events than placebo.
    TNThe New England Journal of Medicine

    The New England Journal of Medicine

    Official Account
    https://www.nejm.org/
    nejm